Tempus AI, Inc. Class A Common Stock

NASDAQ (USD): Tempus AI, Inc. Class A Common Stock (TEM)

Last Price

50.45

Today's Change

0.00 (0.00%)

Day's Change

0.00 - 0.00

Trading Volume

0

Overview

Market Cap

7 Billion

Shares Outstanding

152 Million

Avg Volume

3,310,485

Avg Price (50 Days)

47.35

Avg Price (200 Days)

46.05

PE Ratio

-9.78

EPS

-5.16

Earnings Announcement

26-Feb-2025

Previous Close

47.64

Open

51.80

Day's Range

47.18 - 52.8

Year Range

22.89 - 79.49

Trading Volume

25,455,107

Price Change Highlight

1 Day Change

5.90%

5 Day Change

43.53%

1 Month Change

44.51%

3 Month Change

11.10%

6 Month Change

23.96%

Ytd Change

47.30%

1 Year Change

25.34%

3 Year Change

25.34%

5 Year Change

25.34%

10 Year Change

25.34%

Max Change

25.34%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Healthcare

Description:

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment